Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Carbapenem-resistant Acinetobacter Baumannii
100%
Israel
97%
Colistin
82%
Bloodstream Infection
58%
Escherichia Coli
36%
COVID-19
32%
Multidrug-resistant Gram-negative Bacteria
32%
Bacteremia
29%
Combination Therapy
28%
Randomized Controlled Trial
27%
Retrospective Cohort Study
26%
Israeli
25%
Monotherapy
25%
Severe Infection
25%
Meropenem
24%
Carbapenemase-producing Enterobacterales
24%
Acinetobacter Baumannii (A. baumannii)
22%
Colorectal Surgery
22%
National Cohort Study
22%
Carbapenem-resistant Enterobacterales
20%
Antimicrobial Resistance
20%
Colistin-meropenem
19%
Clinical Failure
19%
95% Confidence Interval
19%
Carbapenem Resistance
19%
Healthcare Workers
18%
Carbapenemase
18%
14-day Mortality
18%
Carbapenem-resistant Gram-negative Infections
17%
Carbapenemases
17%
Hospitalized Patients
17%
Murine Model
16%
Hospital-onset
15%
Case Fatality Rate
15%
30-day Mortality
14%
Human Adenovirus Type 55
14%
Human Infection
14%
ESBL-PE
14%
In Vivo Fitness
14%
Ertapenem
14%
Enterobacterales
14%
Surgical Site Infection
14%
Clinical Outcomes
14%
Sentinel
13%
Quick Sequential Organ Failure Assessment (qSOFA)
13%
Acute Hospital
12%
Colistin-resistant
12%
Carbapenem-resistant Acinetobacter Baumannii Infection
12%
Blood Culture
12%
Ceftazidime-avibactam
11%
Pharmacology, Toxicology and Pharmaceutical Science
Carbapenem
99%
Bloodstream Infection
67%
Colistimethate
63%
Infection
53%
Acinetobacter Baumannii
44%
Meropenem
34%
Gram Negative Bacterium
27%
Antimicrobial Agent
25%
Randomized Controlled Trial
25%
Combination Therapy
19%
Gram Negative Infection
17%
Monotherapy
16%
Escherichia coli
16%
Bacterium
15%
Ertapenem
14%
Antibiotics
14%
Extended Spectrum Beta Lactamase
13%
Diseases
12%
Randomized Clinical Trial
9%
Carbapenemase
9%
Third Generation Cephalosporin
9%
Enterobacteriaceae
8%
Penicillinase
8%
Infectious Agent
8%
Staphylococcus Aureus
8%
Surgical Infection
8%
Acinetobacter Infection
8%
Pharmacokinetics
8%
Metronidazole
8%
Bacterial Infection
8%
Cohort Study
7%
Prospective Study
7%
Asthma
7%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
7%
Synergism
7%
Case-Control Study
7%
Beta Lactamase Inhibitor
7%
Beta Lactam
7%
Medical Cannabis
7%
Influenza
7%
Vaccination
7%
Cefiderocol
7%
Ovary Cancer
7%
Coronavirinae
7%
Cefuroxime
7%
Thrombocytosis
7%
Adenoviridae
7%
Salicylate Sodium
7%
Clinical Study
7%
Pneumonia
6%
Medicine and Dentistry
Infection
55%
Carbapenem
54%
Bloodstream Infection
45%
COVID-19
29%
Gram-Negative Bacteria
28%
Acinetobacter Baumannii
26%
Colistimethate
23%
Randomized Controlled Trial
23%
Colorectal Surgery
22%
Surgical Infection
16%
Meropenem
15%
Escherichia coli
15%
Antibiotic Resistance
15%
Prospective Study
14%
Ertapenem
14%
Antimicrobial Stewardship
14%
Pathogen
13%
Extended Spectrum Beta Lactamase
13%
Antibiotics
12%
Retrospective Cohort Study
11%
Intensive Care Unit
11%
Antibiotic Therapy
11%
Health Care Personnel
11%
Combination Therapy
9%
Third Generation Cephalosporin
9%
Colectomy
9%
Health Care Cost
9%
Metronidazole
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Biological Marker
8%
Inflammation
8%
Staphylococcus Aureus
8%
Penicillinase
8%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
8%
Bacterial Infection
8%
Antibiotic Prophylaxis
8%
Diseases
7%
Gram-Negative Bacterial Infection
7%
Adenoviridae
7%
Systematic Review
7%
PARP Inhibitor
7%
β-Lactamase inhibitor
7%
Beta Lactamase Inhibitor
7%
Subretinal Fluid
7%
Cohort Studies
7%
Seroprevalence
7%
Oral
7%
Diabetic Retinopathy
7%
Estriol
7%
Solid Organ Transplantation
7%